Alecensa 150mg Capsule

About

Alecensa (Alectinib) is a highly selective anaplastic lymphoma kinase (ALK) inhibitor indicated for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC). This advanced medication works by specifically blocking the activity of the ALK protein, a key driver of cancer cell proliferation and survival in certain types of lung cancer. When the ALK protein is overactive, it leads to uncontrolled cell growth and tumor development. By inhibiting this specific molecular target, Alecensa effectively helps to slow or stop the growth and spread of cancer cells throughout the body, including to the brain. Clinical trials have consistently demonstrated its superior effectiveness in improving progression-free survival and overall response rates in patients with ALK-positive NSCLC, including those with central nervous system metastases. It represents a crucial targeted therapy approach, offering a more precise and often more effective treatment option for eligible patients compared to traditional chemotherapy, thereby improving patient outcomes and quality of life.

Uses

• Treatment of ALK-positive metastatic NSCLC.
• First-line therapy for ALK-positive NSCLC.
• Treatment after progression on crizotinib for ALK-positive NSCLC.
• Management of brain metastases in ALK-positive NSCLC.

Directions For Use

Take the capsules orally with food, as prescribed by your oncologist. Swallow whole, do not open or chew.

Benefits

• Targets ALK-positive cancer cells specifically.
• Effective in metastatic non-small cell lung cancer.
• Can penetrate the blood-brain barrier.
• May improve progression-free survival.
• Offers a targeted treatment option.
• Helps reduce tumor size and spread.

Side Effects

• Fatigue
• Constipation
• Edema (swelling)
• Myalgia (muscle pain)
• Anemia
• Rash
• Liver enzyme elevation
• Bradycardia (slow heart rate)
• Photosensitivity
• Nausea
• Diarrhea
• Vision impairment

Safety Measures

• Alcohol - Avoid alcohol as it may exacerbate side effects or interact with the medication. Consult your doctor.
• Pregnancy - This medication can cause fetal harm. Effective contraception is required during treatment and for a period after.
• Breastfeeding - It is not recommended to breastfeed during treatment and for a period after the last dose due to potential harm to the infant.
• Liver - Monitor liver function closely. Dose adjustments or interruption may be needed for severe hepatic impairment.
• Kidney - Use with caution in patients with severe renal impairment. No specific dose adjustment is typically required for mild to moderate.
• Lung - Interstitial lung disease/pneumonitis can occur. Monitor for new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.